BAM15
Also known as: N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine
BAM15 (also called N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a small molecule in the Mitochondrial Uncoupler (Protonophore) class. Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.
For research use only.
Key Facts
- CAS
- 210302-17-3
- Molecular Weight (MW)
- 340.29 g/mol
- Half-life
- Not established (limited public PK; primarily preclinical/in vitro characterization)
- FDA status
- Not Approved
- Administration Route
- In vitro / preclinical research use (route varies by study design)
- Frequency
- Not established
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Mitochondrial inner membrane
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Dec 2025, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg
- $5.29/mg
Research summary
Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide.
Peptide Library's BAM15 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Not established (research-only)
- Frequency
- Not established
- Cycle
- Not established (research compound; do not self-administer)
- Administration Route
- In vitro / preclinical research use (route varies by study design)
- Reconstitution Guide
- Typically dissolved in DMSO for lab use; follow COA/MSDS and lab SOPs
- Concentration Example
- Stock solutions commonly prepared for in vitro assays (vendor guidance varies)
- Expected Onset
- Acute mitochondrial respiration effects in vitro
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. BAM15 is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Amino acid sequence | N/A (small-molecule mitochondrial protonophore; not a peptide) |
|---|---|
| Molecular formula | C16H10F2N6O |
| Molecular weight | 340.29 g/mol |
| CAS number | 210302-17-3 |
| Half-life | Not established (limited public PK; primarily preclinical/in vitro characterization) |
| Appearance | Yellow to orange solid/powder (typical small-molecule appearance; vendor-dependent) |
| Formulation | Lyophilized Powder |
| PubChem CID | 565708 |
| ChEMBL | CHEMBL3627755 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.
Origin
Synthetic oxadiazolopyrazine small molecule.
Targets
Studies
- Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15
- BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
- BAM15 improves oocyte quality against obesity via PPARγ-dependent mitochondrial function
- BAM15 inhibits endothelial pyroptosis via the NLRP3/ASC/caspase-1 pathway to alleviate atherosclerosis
- Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease
Regulatory & research status
BAM15 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
BAM15 side effects
Side Effects
- Hyperthermia risk class-effect of uncouplers
- No approved human dose
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
BAM15: frequently asked questions
What is BAM15?
Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide.
How does BAM15 work?
Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.
Is BAM15 FDA approved?
No. BAM15 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of BAM15?
Reported half-life for BAM15 is Not established (limited public PK; primarily preclinical/in vitro characterization). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of BAM15?
BAM15 has the sequence N/A (small-molecule mitochondrial protonophore; not a peptide), giving a chain of 2 amino acids. Its molecular formula is C16H10F2N6O.
What peptides are similar to BAM15?
Compounds most often compared with BAM15 include 5-Amino-1MQ, SLU-PP-332, AICAR and Tesofensine. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- PubChem BAM15External reference
- Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15 — Int J Mol Sci, 2025External reference
- BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases — Front Endocrinol (Lausanne), 2023External reference
- BAM15 improves oocyte quality against obesity via PPARγ-dependent mitochondrial function — Protein Cell, 2026External reference
- BAM15 inhibits endothelial pyroptosis via the NLRP3/ASC/caspase-1 pathway to alleviate atherosclerosis — Atherosclerosis, 2025External reference
- Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease — Acta Physiol (Oxf), 2024External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This BAM15 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track BAM15 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →